Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/25/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Martin J. Schlumberger

Wrong Dr. Martin J. Schlumberger?

Email: m***@***.fr
Institut Gustave Roussy
Villejuif ,
France

 
Background

Employment History

  • Professor of Oncology
    University Paris Sud
  • Medullary Specialist
    Service de Médecine Nucléaire
  • Professor of Oncology
    University Paris Su..

Education

  • M.D.
  • MD
34 Total References
Web References
News Page - Bayer HealthCare Pharmaceuticals
pharma.bayer.com, 25 April 2014 [cached]
"European patients with RAI-refractory differentiated thyroid cancer currently have no approved active systemic treatments and are eager for new options that delay the spread of their disease," said Martin Schlumberger, M.D., of Institut Gustave-Roussy in Villejuif, France and co-lead investigator of the DECISION trial.
"We are confident that, based on ...
www.fellowsforcancer.org, 4 June 2014 [cached]
"We are confident that, based on our findings, lenvatinib will eventually become a standard treatment for radioiodine-resistant thyroid cancer," said study lead author Dr Martin Schlumberger, a professor of oncology at the University Paris Sud in Paris, France. Two active drugs "As little as a year ago, this group of patients had no effective treatment options. It's remarkable that we now have two active drugs in this setting, both of them tyrosine kinase inhibitors," he added in a statement provided by the American Society of Clinical Oncology.
Free One-Day Thyroid Cancer Workshop in Baltimore, Maryland, Features Eight Physician Speakers, Saturday, April 16, 2005
www.prweb.com, 28 Mar 2005 [cached]
Martin Schlumberger, M.D., Medullary Specialist, Service de Médecine Nucléaire, France.
"We are confident that, based on ...
www.regionalhospitaljackson.com, 30 July 2014 [cached]
"We are confident that, based on our findings, lenvatinib will eventually become a standard treatment for radioiodine-resistant thyroid cancer," said study lead author Dr. Martin Schlumberger, a professor of oncology at the University Paris Su...
"As the first Phase III study ...
www.bayer.ca, 23 April 2014 [cached]
"As the first Phase III study in RAI-refractory differentiated thyroid cancer to be reported, these positive results represent an advance for patients with this disease who do not currently have a standard therapeutic option," said Martin Schlumberger, M.D., of Institut Gustave-Roussy in Villejuif, France and co-lead investigator of the DECISION trial.
Other People with the name "Schlumberger":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304